Xeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024. In the quarter to June 2026, revenue grew 28.7%, EPS fell 1,700.0%, free cash flow grew 8,403.1% and total debt rose 15.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow XERS
Xeris Biopharma Holdings, Inc. (XERS) Piotroski F-score
Xeris Biopharma Holdings, Inc.'s Piotroski F-score for fiscal 2025 is 8 out of 9: 8 of nine tests of profitability, leverage and efficiency passed, up from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 8 | 4.00 |
| FY2024 | 4 | (1.00) |
| FY2023 | 5 | 1.00 |
| FY2022 | 4 | (1.00) |
| FY2021 | 5 | 0.00 |
| FY2020 | 5 | 4.00 |
| FY2019 | 1 | (2.00) |
| FY2018 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 0.16% | (16.99%) | Pass | 1 |
| Positive operating cash flow | 28.63m | (36.98m) | Pass | 1 |
| Rising return on assets | 0.16% | (16.99%) | Pass | 1 |
| Cash flow above net income | 28.07m | 17.86m | Pass | 1 |
| Falling long-term leverage | 0.62 | 0.67 | Pass | 1 |
| Rising current ratio | 2.19 | 1.67 | Pass | 1 |
| No new shares issued | 160,425,000 | 146,773,000 | Fail | 0 |
| Rising gross margin | 85.41% | 81.86% | Pass | 1 |
| Rising asset turnover | 0.83 | 0.63 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 8 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| XERS Xeris Biopharma Holdings, Inc. | 8 |
| ANIP ANI Pharmaceuticals, Inc. compare | 7 |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 7 |
| PAHC Phibro Animal Health Corporation compare | 6 |
| ETON Eton Pharmaceuticals, Inc. compare | 5 |
| PBH Prestige Consumer Healthcare Inc. compare | 5 |
| SUPN Supernus Pharmaceuticals, Inc. compare | 5 |
| PRGO Perrigo Company plc compare | 4 |
| ALVO Alvotech compare | 3 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover